These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 12907009)

  • 41. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Docetaxel was effective as neoadjuvant chemotherapy for patients after failure of trans-arterial neoadjuvant chemotherapy with CEF in 2 cases of advanced breast cancer].
    Ogawa T; Nagata S; Suzuki H; Onzuka T; Yamanaka N; Kawano R; Yoshida J; Shinohara M; Sumitomo K; Matsuo K; Kuroki S
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1743-5. PubMed ID: 11708023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?
    Hodgkinson VC; ELFadl D; Agarwal V; Garimella V; Russell C; Long ED; Fox JN; McManus PL; Mahapatra TK; Kneeshaw PJ; Drew PJ; Lind MJ; Cawkwell L
    J Proteomics; 2012 Feb; 75(4):1276-83. PubMed ID: 22115752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Current developments in use of docetaxel (taxotere) in gynecologic oncology].
    Jackisch C
    Med Klin (Munich); 1998 Sep; 93 Suppl 3():4-15. PubMed ID: 9796219
    [No Abstract]   [Full Text] [Related]  

  • 47. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers.
    Naoi Y; Tanei T; Kishi K; Tsunashima R; Tominaga N; Baba Y; Nakayama T; Shimazu K; Kim SJ; Tamaki Y; Noguchi S
    Cancer Lett; 2012 Jan; 314(2):206-12. PubMed ID: 22018777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
    Sjöström J; Collan J; von Boguslawski K; Franssila K; Bengtsson NO; Mjaaland I; Malmström P; Østenstad B; Wist E; Valvere V; Bergh J; Skiöld-Petterson D; Saksela E; Blomqvist C
    Eur J Cancer; 2002 Mar; 38(4):535-42. PubMed ID: 11872346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II study of weekly docetaxel in patients with metastatic breast cancer.
    Aihara T; Kim Y; Takatsuka Y
    Ann Oncol; 2002 Feb; 13(2):286-92. PubMed ID: 11886007
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells.
    Brown I; Shalli K; McDonald SL; Moir SE; Hutcheon AW; Heys SD; Schofield AC
    Breast Cancer Res; 2004; 6(5):R601-7. PubMed ID: 15318941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
    Anand A; Anand A
    J Natl Cancer Inst; 1995 Nov; 87(21):1642. PubMed ID: 7563210
    [No Abstract]   [Full Text] [Related]  

  • 55. Docetaxel: an update of its use in advanced breast cancer.
    Figgitt DP; Wiseman LR
    Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Docetaxel therapy against anthracycline resistant breast cancer].
    Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y; Suzuma T; Tanino H
    Gan To Kagaku Ryoho; 1999 May; 26(6):781-8. PubMed ID: 10410147
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer.
    Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
    Breast Cancer; 2002; 9(2):166-9. PubMed ID: 12016397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
    Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
    Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of docetaxel in improving treatment outcomes in advanced breast cancer.
    Rubens RD
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S1-2. PubMed ID: 9486094
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.